Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Clin Pediatr. Dec 9, 2026; 15(4): 121145
Published online Dec 9, 2026. doi: 10.5409/wjcp.121145
Published online Dec 9, 2026. doi: 10.5409/wjcp.121145
Intravenous immunoglobulin in pediatric critical care: Bridging evidence gaps and guiding rational use
Amit Agrawal, Department of Pediatrics, Gandhi Medical College, Hamidia Hospital Campus, Bhopal 462001, Madhya Pradesh, India
Author contributions: Agrawal A was responsible for concept, literature review, drafting and manuscript editing, revising the article critically for important intellectual content.
Conflict-of-interest statement: The author declares no conflict of interest in publishing the manuscript.
Corresponding author: Amit Agrawal, Associate Professor, Department of Pediatrics, Gandhi Medical College, Hamidia Hospital Campus, 49-B Indrapuri, B-Sector, Bhopal 462001, Madhya Pradesh, India. agrawaldramit@yahoo.co.in
Received: March 17, 2026
Revised: April 23, 2026
Accepted: May 27, 2026
Published online: December 9, 2026
Processing time: 186 Days and 20.8 Hours
Revised: April 23, 2026
Accepted: May 27, 2026
Published online: December 9, 2026
Processing time: 186 Days and 20.8 Hours
Core Tip
Core Tip: Intravenous immunoglobulin is increasingly being utilized in pediatric intensive care units for its diverse immunomodulatory effects, even beyond established indications. The study by Varadarajan et al highlights substantial off-label use with only a few adverse effects. This editorial provides a practical, evidence-based framework for the use of intravenous immunoglobulin in critically ill children, including indications, strength of evidence, and stewardship principles to guide its rational use.